Dr. John Leonard on Top Lymphoma Studies at the 2015 ASH Annual Meeting
Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease
John Leonard, MD, medical oncologist, Weill Cornell Medicine and NewYorkPresbyterian Hospital , discusses the top lymphoma studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting. Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease a duet of brentuximab vedotin and ipilimumab.
Leonard goes on to say there is more data that involves brentuximab alongside chemotherapy in elderly patients, which would be in place of ABVD chemotherapy. ABVD chemotherapy is a standard of care for older patients with Hodgkin's lymphoma, though the treatment has proven less effective and more toxic to patients over time.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
In SCLC, Upfront BMS-986012 Plus Nivolumab/Chemotherapy Has Potential
September 13th 2024The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.
Read More
Consolidation Durvalumab Shows Consistent Survival Improvements in LS-SCLC Subgroups
September 13th 2024The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.
Read More
